Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05080205
Other study ID # BariBrain-PET
Secondary ID T153/2018
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date February 11, 2019
Est. completion date December 2022

Study information

Verified date October 2021
Source Turku University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background: Morbid obesity is associated with decreased brain µ-opioid receptor availability, possibly resulting in higher food intake needed to gain pleasure from eating. This decrease seems to normalize already 6 months after bariatric surgery, but the longer-term effects have not been studied. Obesity and insulin resistance result in significantly increased brain insulin-stimulated glucose uptake, whereas in every other tissue glucose uptake is lower. One possible explanation to this could be central inflammation and activation of brain glial cells, which has been shown to occur in animal models of obesity. Obesity has also been shown to associate with increased risk of Alzheimer's disease and cognitive decline in several studies. Aims: The first objective of this study is to both study the effects of bariatric surgery as well as compare the effects of gastric bypass and sleeve gastrectomy on food-associated pleasure, extending the follow-up period to 2 years postoperatively. The second aim is to investigate the effect of morbid obesity and weight loss on brain inflammation and gliosis and its association with increased brain insulin-stimulated glucose uptake. Furthermore, association of obesity, insulin resistance, central inflammation and neurocognitive dysfunction are evaluated.


Description:

Methods: A total of 60 morbidly obese subjects, 30 assigned for Roux-en-Y gastric bypass and 30 for sleeve gastrectomy according to routine treatment protocols will be recruited for this study. A control group of 30 healthy subjects will also be recruited. We will perform 1) structural MRI and MRS, 2) functional MRI during tasting and visual food cues, 3) PET imaging of µ-opioid receptor availability using [11C]-carfentanil, 4) PET imaging of cerebral inflammation and astrocyte activation using [11C]-PK11195, 5) measurement of whole-body and tissue insulin sensitivity by combining hyperinsulinemic, euglycemic clamp with [18F]-FDG-PET, 6) neuropsychological testing. The control group will only be studied once, whereas study procedures will be repeated for the morbidly obese before very-low calorie diet and 6, 12 and 24 months postoperatively.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 30
Est. completion date December 2022
Est. primary completion date October 10, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion criteria: Morbidly obese group 1. BMI 35.0-45.0 kg/m2, or BMI 32.0-45.0 kg/m2 and diagnosed diabetes 2. Age 18-60 years 3. Eligible to bariatric surgery evaluated according to normal treatment paradigm Non-obese controls 1. BMI 18-27 kg/m2 2. Age 18-60 years 3. Fasting plasma glucose =6.1 mmol/L 4. Normal values in 2-hour oral glucose tolerance test Exclusion criteria: Morbidly obese group 1. Metal objects in the body (including pacemakers, metallic artificial valve prostheses, inner ear implants, surgical clipses, braces, foreign fragments) 2. Previous participation in PET studies 3. Pregnancy 4. Poor compliance, alcohol or drug abuse 5. Weight over 150 kg or waist circumference over 150 cm 6. Diabetes with fasting glucose levels =7.0 mmol/L, or treatment with insulin 7. Any chronic disease, medication or condition that could create a hazard to subject safety, endanger study procedures or interfere with the interpretation of results. Non-obese controls 1. Metal objects in the body (including pacemakers, metallic artificial valve prostheses, inner ear implants, surgical clipses, braces, foreign fragments) 2. Previous participation in PET studies 3. Pregnancy 4. Poor compliance, alcohol or drug abuse 5. Smoking 6. History of eating disorders, drastic weight-gain or weight-loss 7. History of psychiatric disorders 8. Any chronic disease, medication or condition that could create a hazard to subject safety, endanger study procedures or interfere with the interpretation of results

Study Design


Intervention

Procedure:
Bariatric surgery
Roux-en-Y gastric bypass or sleeve gastrectomy, chosen based on routine evaluation process

Locations

Country Name City State
Finland Turku PET Centre Turku

Sponsors (1)

Lead Sponsor Collaborator
Turku University Hospital

Country where clinical trial is conducted

Finland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in central inflammation Assessment of brain glial cell activation using [11C]-PK11195 tracer and positron emission tomography Controls: 0 months; Morbidly obese: preoperatively, 6 months postoperatively
Secondary Changes in central reward system using fMRI imaging Assessment of brain reward system activation after visual/taste cues using functional MRI Controls: 0 months; Morbidly obese: preoperatively, 6 months, 12 months, 24 months postoperatively
Secondary Changes in brain µ-opioid receptor availability using PET imaging Assessment of brain µ-opioid receptor availability using [11C]-carfentanil tracer and positron emission tomography Controls: 0 months; Morbidly obese: preoperatively, 6 months, 12 months postoperatively
Secondary Changes in cognitive function studied with testing Neuropsychological testing focusing on memory, decision-making and inhibition Controls: 0 months; Morbidly obese: preoperatively, 6 months, 12 months, 24 months postoperatively
Secondary Changes in whole-body insulin sensitivity usign FDG-PET imaging Assessment of whole-body insulin sensitivity using hyperinsulinemic, euglycemic clamp Controls: 0 months; Morbidly obese: preoperatively, 6 months postoperatively
Secondary Changes in tissue-specific insulin sensitivity using FDG-PET imaging Assessment of insulin-stimulated glucose uptake in the brain, liver, skeletal muscle and adipose tissue by performing positron emission tomography with [18F]-fluorodeoxyglucose tracer during hyperinsulinemic, euglycemic clamp Controls: 0 months; Morbidly obese: preoperatively
See also
  Status Clinical Trial Phase
Completed NCT03142633 - MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome
Recruiting NCT04984226 - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD Phase 2
Recruiting NCT05354245 - Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL) N/A
Completed NCT03383822 - Regulation of Endogenous Glucose Production by Brain Insulin Action in Insulin Resistance Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Suspended NCT03652987 - Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
Completed NCT04203238 - Potato Research for Enhancing Metabolic Outcomes N/A
Recruiting NCT03658564 - Preoperative Oral Carbohydrate Treatment Minimizes Insulin Resistance N/A
Completed NCT04183257 - Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics Phase 4
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT03627104 - Effect of Dietary Protein and Energy Restriction in the Improvement of Insulin Resistance in Subjects With Obesity N/A
Completed NCT05124847 - TREating Pediatric Obesity N/A
Active, not recruiting NCT03288025 - Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE) N/A
Completed NCT03809182 - Effect of Dexmedetomidine on Postoperative Glucose and Insulin Levels. Phase 4
Completed NCT01809288 - Identifying Risk for Diabetes and Heart Disease in Women
Completed NCT04642482 - Synbiotic Therapy on Intestinal Microbiota and Insulin Resistance in Obesity Phase 4
Terminated NCT03278236 - Does Time Restricted Feeding Improve Glycaemic Control in Overweight Men? N/A
Not yet recruiting NCT06159543 - The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes N/A
Withdrawn NCT04741204 - Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer Phase 4
Not yet recruiting NCT05540249 - Pre-operative Carbohydrates in Diabetic Patients Undergoing CABG N/A